Modulatory effects of bortezomib on host immune cell functions.

Immunotherapy
Samuel Troy PellomAnil Shanker

Abstract

Bortezomib is an inhibitor of the ubiquitin-proteasome proteolytic pathway responsible for intracellular protein turnover. Cellular proteins controlled by this pathway represent a diverse group of potential therapeutic targets, particularly in cancer cells, which exploit this proteasomal pathway to promote their growth and diminish apoptosis. Along with inhibiting the proteasome and thus sensitizing tumor cells to apoptosis, bortezomib may also have multiple effects on the host immune responses. This review summarizes the effects that bortezomib may play on immune cell subsets in various disease states in modifying lymphocyte receptors, ligands, the expression of various cytokines and chemokines and their downstream signaling. We also propose steps that can be taken to refine combinatorial strategies that include bortezomib to improve current immunotherapeutic approaches.

References

Oct 6, 1998·Annual Review of Biochemistry·A Hershko, A Ciechanover
Mar 29, 2001·Nature Immunology·B Moser, P Loetscher
May 19, 2004·Proceedings of the National Academy of Sciences of the United States of America·Kai SunWilliam J Murphy
Oct 6, 2004·British Journal of Haematology·S JagannathK C Anderson
Dec 23, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Owen A O'ConnorAndrew D Zelenetz
Feb 3, 2005·Nature Reviews. Molecular Cell Biology·Aaron Ciechanover
May 4, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Tahira KhanJon M Wigginton
Jul 26, 2006·Experimental Hematology·Hal E Broxmeyer
Aug 24, 2007·Advances in Experimental Medicine and Biology·Anil Shanker, Thomas Sayers
Dec 22, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·William H D HallettWilliam J Murphy
Feb 7, 2008·European Journal of Immunology·Paolo CascioRoberto Sitia
Jun 4, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sorin ArmeanuHelmut R Salih
Aug 20, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Asher Chanan-KhanPaul G Richardson
Jan 24, 2009·Nature Reviews. Immunology·Derk AmsenRichard A Flavell
May 6, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·James E ButlerCharles T Lutz
Jun 16, 2009·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Tianhong LiRasim Gucalp
Dec 23, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Andreas LundqvistRichard Childs
Feb 25, 2010·Cancer Research·Jens Michael SeegerHamid Kashkar
Apr 8, 2010·Clinical Lymphoma, Myeloma & Leukemia·Ulrike HeiderOrhan Sezer
Apr 8, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Ashenafi Y TilahunGovindarajan Rajagopalan
Oct 12, 2010·Journal of Molecular Cell Biology·Youming Xie
Dec 21, 2010·International Journal of Cancer. Journal International Du Cancer·Seiko IwataHiroshi Kimura
Mar 3, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shirin Arastu-KapurChristopher J Kirk
Oct 4, 2011·Cellular Oncology (Dordrecht)·Feng ChenYulia Nefedova

❮ Previous
Next ❯

Citations

Jan 24, 2016·Cellular and Molecular Life Sciences : CMLS·Camille GuillereyMark J Smyth
Apr 22, 2017·Cancer Treatment Reviews·Leo RascheFaith E Davies
Nov 27, 2018·Expert Opinion on Investigational Drugs·I-Tao HuangJason C Steel
Dec 27, 2018·British Journal of Haematology·Xiaoping LiXi Zhang
Feb 2, 2019·Annals of Hematology·C PfrepperS Petros
May 8, 2018·Journal of Leukocyte Biology·Pan LiuFuling Zhou
Dec 7, 2019·Hematology·Ecem SevimDoruk Erkan
Oct 11, 2017·Frontiers in Immunology·Alessandra ZingoniAlessandra Soriani
Feb 26, 2019·Frontiers in Immunology·Smita Y PatelStephen Jolles
Dec 10, 2019·European Journal of Haematology·Faye A SharpleyAshutosh D Wechalekar
Oct 4, 2020·Expert Review of Clinical Pharmacology·Bénédict Fallet, Ulrich A Walker
Aug 15, 2019·Molecular Cancer Research : MCR·Ofrat Beyar-KatzYuval Shaked
Jan 21, 2021·Biomedicines·Claudio TabolacciFrancesco Facchiano
Apr 12, 2021·Best Practice & Research. Clinical Rheumatology·Maria Martin-Lopez, Patricia E Carreira
Oct 4, 2020·The Urologic Clinics of North America·Nina BhardwajJohn P Sfakianos
Oct 12, 2021·Transplantation and Cellular Therapy·Murali JanakiramJeffrey S Miller

❮ Previous
Next ❯

Methods Mentioned

BETA
RIP

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

Expert Opinion on Therapeutic Targets
Min ShenQ Ping Dou
Journal of the National Comprehensive Cancer Network : JNCCN
George N DeMartino
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
Annette AltmannUwe Haberkorn
© 2021 Meta ULC. All rights reserved